AWMSG issues Final Appraisal Recommendation on argatroban (Exembol®) for anticoagulation in patients with heparin-induced thrombocytopenia type II

Source: All Wales Medicines Strategy Group (AWMSG) Area: Evidence > Drug Specific Reviews In its Final Appraisal Recommendation, the All Wales Medicines Strategy Group (AWMSG) is of the opinion that argatroban (Exembol®) 100 mg/ml concentrate for solution for infusion, is appropriate for specialist only prescribing within NHS Wales for anticoagulation in adult patients with heparin-induced thrombocytopenia type II who require parenteral antithrombotic therapy. The diagnosis should be confirmed by the HIPAA (heparin induced platelet activation assay) or an equivalent test. However, such confirmation must not delay the start of treatment.
Source: NeLM - Drug Specific Reviews - Category: Drugs & Pharmacology Source Type: news